Sunshine Biopharma Inc (SBFM)

[DDA]

https://sec.report/Document/0001683168-22-000126/



Sunshine Biopharma, Inc.

6500 Trans-Canada Highway

4th Floor

Pointe-Claire, Quebec, Canada H9R 0A5



January __, 2022



Dear Shareholders:



The enclosed Information Statement is being furnished to the holders of record of the shares of the common stock, with a par value of $0.001 per share (the “Common Stock”), of Sunshine Biopharma, Inc., a Colorado corporation (the “Company), as of the close of business on the new record date, January 3, 2022 (the “New Record Date”). The purpose of the Information Statement is to notify our shareholders that on December 24, 2021, the Company received a written consent in lieu of a meeting (the “Board Consent”) from the members of the board of directors of the Company (the “Board”) and a written consent in lieu of a meeting from the holders of approximately 70.6% of the voting stock (the “Consenting Shareholders”) of the Company (the “Shareholder Consent” and together with the Board Consent, the “Written Consents”). The Written Consents adopted resolutions to increase the ratio of a reverse stock split that had previously been filed in definitive form on October 6, 2021 from a ratio of no more than 1-for-100 to a ratio of no more than 1-for 500, with the exact ratio to be determined by the Board in its sole discretion (the “Reverse Split”), and with such Reverse Split to be effective at such time and date, if at all, as determined by the Board in its sole discretion. The revised reverse split ratio and the New Record Date will only be utilized if the price of our common stock on the effective date of the Reverse Split is insufficient to allow the common stock to qualify for listing on Nasdaq. If we utilize the previously approved ratio, we will use the original Record Date of September 8, 2021.



You are urged to read this Information Statement in its entirety for a description of the actions taken by the Consenting Shareholders of the Company. If it is necessary to use the increased ratio, the actions will only become effective on a date that is not earlier than twenty-one (21) calendar days after this Information Statement is first mailed to our shareholders.



WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.



No action is required by you. The enclosed Information Statement is being furnished to you to inform you that the foregoing actions have been approved by the Consenting Shareholders. Because the Consenting Shareholders have voted in favor of the foregoing actions, and have sufficient voting power to approve such actions, no other shareholder consents will be solicited in connection with the transactions described in this Information Statement. The Board is not soliciting your proxy, and proxies are not requested from shareholders.



This Information Statement is being mailed on or about January __, 2022 to shareholders of record on the New Record Date.






Sincerely,



/s/ Dr Steve N. Slilaty

Dr. Steve N. Slilaty

Chief Executive Officer










PRELIMINARY COPY



Sunshine Biopharma, Inc.

6500 Trans-Canada Highway

4th Floor

Pointe-Claire, Quebec, Canada H9R 0A5

[phone]



INFORMATION STATEMENT

PURSUANT TO SECTION 14(C)

OF THE SECURITIES EXCHANGE ACT OF 1934

AND RULE 14C-2 THEREUNDER

_____________________________________